SJOGREN’S SYNDROME MARKET ANALYSIS

Sjogren’s Syndrome Market, by Drug (Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids and Others (Pain Relief Medication and late phase drug)), by type (Primary and Secondary), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022
Code : CMI5210
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Treatments currently available either only treat the symptoms or are viewed as ineffective by many patients

Global Sjogren’s syndrome Market: Restraint

Many of the Sjogren’s treatments that are currently available either only treat the symptoms or are viewed as ineffective by many patients. For instance, according to data published in September 2021, on Frontiers Media Journal, in a randomized trial, hydroxychloroquine (HCQ) did not significantly reduce the symptoms of primary Sjogren’s after 24 weeks of treatment when compared to placebo. In a similar other studies came to the same conclusion that hydroxychloroquine (HCQ) is not a successful treatment for primary Sjorgens.